69 related articles for article (PubMed ID: 22765024)
21. Association between CYP3A5 polymorphisms and blood pressure in kidney transplant recipients receiving calcineurin inhibitors.
Ferraresso M; Turolo S; Ghio L; Tirelli AS; Belingheri M; Villa R; Groppali E; Edefonti A
Clin Exp Hypertens; 2011; 33(6):359-65. PubMed ID: 21851254
[TBL] [Abstract][Full Text] [Related]
22. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters.
Takeuchi H; Okuyama K; Konno O; Jojima Y; Akashi I; Nakamura Y; Iwamoto H; Hama K; Iwahori T; Uchiyama M; Ashizawa T; Matsuno N; Nagao T; Hirano T; Oka K
Transplant Proc; 2005 May; 37(4):1745-7. PubMed ID: 15919452
[TBL] [Abstract][Full Text] [Related]
23. Renal function in cardiac transplant recipients: retrospective analysis of 133 consecutive patients in a single center.
Tinawi M; Miller L; Bastani B
Clin Transplant; 1997 Feb; 11(1):1-8. PubMed ID: 9067686
[TBL] [Abstract][Full Text] [Related]
24. Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
Lloberas N; Torras J; Cruzado JM; Andreu F; Oppenheimer F; Sánchez-Plumed J; Gentil MÁ; Brunet M; Ekberg H; Grinyó JM;
Nephrol Dial Transplant; 2011 Nov; 26(11):3784-93. PubMed ID: 21427078
[TBL] [Abstract][Full Text] [Related]
25. Prednisone withdrawal in pediatric kidney transplant recipients on tacrolimus-based immunosuppression: four-year data.
Hamiwka LA; Burns A; Bell L
Pediatr Transplant; 2006 May; 10(3):337-44. PubMed ID: 16677358
[TBL] [Abstract][Full Text] [Related]
26. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients.
Press RR; Ploeger BA; den Hartigh J; van der Straaten T; van Pelt J; Danhof M; de Fijter JW; Guchelaar HJ
Ther Drug Monit; 2009 Apr; 31(2):187-97. PubMed ID: 19258929
[TBL] [Abstract][Full Text] [Related]
27. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
28. Cyclosporine trough levels in renal graft recipients.
Jauhari H; Wadhawan S; Yashpal ; Kumar A
J Indian Med Assoc; 1999 Nov; 97(11):476-7. PubMed ID: 10638120
[TBL] [Abstract][Full Text] [Related]
29. Evolution of the therapeutic drug monitoring of cyclosporine.
Citterio F
Transplant Proc; 2004 Mar; 36(2 Suppl):420S-425S. PubMed ID: 15041378
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin.
Cholongitas E; Shusang V; Germani G; Tsochatzis E; Raimondo ML; Marelli L; Senzolo M; Davidson BR; Patch D; Rolles K; Burroughs AK
Clin Transplant; 2011; 25(4):614-24. PubMed ID: 20718824
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinase-3 gene polymorphism in renal transplant patients with gingival overgrowth.
Drozdzik A; Kurzawski M; Lener A; Kozak M; Banach J; Drozdzik M
J Periodontal Res; 2010 Feb; 45(1):143-7. PubMed ID: 19778329
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic behavior of cyclosporine A in liver dysfunction.
Kihira K; Kadoyama M; Miyake K; Kitaura T; Kimura Y; Yoshida M; Fukuchi H
Hiroshima J Med Sci; 1994 Dec; 43(4):175-8. PubMed ID: 7883584
[TBL] [Abstract][Full Text] [Related]
33. Effect of active infection on cytochrome P450-mediated metabolism of cyclosporine in renal transplant patients.
Hegazy SK; Adam AG; Hamdy NA; Khalafallah NM
Transpl Infect Dis; 2015 Jun; 17(3):350-60. PubMed ID: 25702620
[TBL] [Abstract][Full Text] [Related]
34. Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients.
Sud K; Muthukumar T; Singh B; Garg SK; Kohli HS; Jha V; Gupta KL; Sakhuja V
Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):647-9. PubMed ID: 11256238
[TBL] [Abstract][Full Text] [Related]
35. Final height in a prospective trial of late steroid withdrawal after pediatric renal transplantation treated with cyclosporine and mizoribine.
Motoyama O; Hasegawa A; Aikawa A; Shishido S; Honda M; Tsuzuki K; Kinukawa T; Hattori M; Ogawa O; Yanagihara T; Saito K; Takahashi K; Ohshima S
Pediatr Transplant; 2012 Feb; 16(1):78-82. PubMed ID: 22122015
[TBL] [Abstract][Full Text] [Related]
36. Total serum bile acids in renal transplanted patients receiving cyclosporine A.
Tripodi V; Nuñez M; Carducci C; Mamianetti A; Agost Carreño C
Clin Nephrol; 2002 Nov; 58(5):350-5. PubMed ID: 12425485
[TBL] [Abstract][Full Text] [Related]
37. Genetic variations of the xenoreceptors NR1I2 and NR1I3 and their effect on drug disposition and response variability.
Mbatchi LC; Brouillet JP; Evrard A
Pharmacogenomics; 2018 Jan; 19(1):61-77. PubMed ID: 29199543
[TBL] [Abstract][Full Text] [Related]
38. Intra- and interindividual variability in the free fraction of cyclosporine in plasma in recipients of renal transplants.
Lindholm A; Henricsson S
Ther Drug Monit; 1989 Nov; 11(6):623-30. PubMed ID: 2595741
[TBL] [Abstract][Full Text] [Related]
39. The effect of ethanol on serum cyclosporine A levels in renal transplant recipients.
Paul MD; Parfrey PS; Smart M; Gault H
Am J Kidney Dis; 1987 Aug; 10(2):133-5. PubMed ID: 3300294
[TBL] [Abstract][Full Text] [Related]
40. Relationship between apparent total body clearance of cyclosporin A and its erythrocyte-to-plasma distribution ratio in renal transplant patients.
Shibata N; Minouchi T; Yamaji A; Park KI; Inoue H; Tomoyoshi T; Sako H; Abe H; Kodama M; Nakane Y
Biol Pharm Bull; 1995 Jan; 18(1):115-21. PubMed ID: 7735224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
